GlaxoSmithKline CEO Andrew Witty is still counting on new respiratory meds to help pull the company out of the financial doldrums, and he has a new inhaler plant in ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a prescription drug that’s used to treat COPD and asthma. Trelegy Ellipta comes as an inhaler. To learn ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using TRELEGY ELLIPTA? TRELEGY ELLIPTA contains the active ...

This is the eighth FDA clearance Propeller Health has received for its respiratory therapy platform. Propeller had previously earned the CE Mark in Europe and approval by Health Canada to sell the ...

Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...

Incruse Ellipta Inhaler Approved for COPD GlaxoSmithKline announced that the FDA has approved Incruse Ellipta (umeclidinium) inhaler for the long-term, once-daily, maintenance treatment of airflow ...